Precision Peptide orders 20,000 thymosin alpha-1 patches for US launch
Delivery of the transdermal patches is expected in January 2027, with a commercial launch to follow subject to final quality review.
TR
By Tom Reyes · Markets Editor
Oct 7 13:38 ETSource: TradingView
The wire
- 01The company ordered 20,000 thymosin alpha-1 transdermal patches for its initial US commercial run, following earlier testing and expanding its peptide patch lineup.
- 02A transdermal thymosin alpha-1 product would give clinics an alternative delivery route for an immune peptide currently handled through injection and compounding channels.
- 03No firm launch date, sell-through data or distribution and wholesale agreements have been disclosed; the item is based on a company press release distributed by TMX Newsfile.
From the source
Read at tradingview.comThe Precision Peptide Company Orders 20,000 TA1 Patches for U.S. Launch
The Precision Peptide Company ordered 20,000 Thymosin Alpha-1 transdermal patches for its initial U.S. commercial run, with delivery expected in Jan 2027 and a launch to follow, subject to final quality review.
